Cholecystokinin (CCK) and its receptors are abundantly represented in the central nervous system. However, a specific role or mechanism ofaction for CCK in this context has not been established. CCK coexists with oxytocin in magnocellular neurons of the hypothalamic-neurohypophysial system, sharing common neurosecretory vesicles with oxytocin in the neural lobe of the pituitary. The neural lobe, which consists primarily of oxytocin-and vasopressin-containing axons and nerve terminals and their surrounding glia, provides a relatively simple model system allowing for the study of the regulation of neurosecretion at the nerve terminal level, free from the complex array of synaptic effects present throughout the rest of the central nervous system. In this paper, we demonstrate the presence ofhigh-affinity CCK binding sites in the rat neural lobe and show that activation of these receptors by the sulfated octapeptide, CCK-8, and related peptides causes potent secretion of oxytocin and vasopressin from the isolated nerve terminals. The secretagogue action of CCK-8, which is blocked by a CCK receptor antagonist (L-364,718), is independent of electrical stimulation and extracellular calcium and is blocked by an inhibitor of protein kinase C. Thus, the action of CCK on the neural lobe provides an example of peptide ligand-induced neurosecretion apparently mediated by second messengers rather than depolarization-induced calcium influx.
Since cholecystokinin (CCK) is colocalized in neurosecretory granules with oxytocin (OT) in the hypothalamicneurohypophysial system (18) , it would be expected that these two peptides are co-released from the nerve terminals of the neural lobe (NL). Supporting this view are the observations that CCK immunoreactivity is lost as a result of stalk section, and physiologic stimuli that result in depletion of OT also cause a marked depletion of NL CCK (1) . The molar concentration of CCK in the rat NL is several orders of magnitude less than that of OT (1) , suggesting that the CCK secreted with OT plays a local rather than systemic role. Since other colocalized peptides-namely, dynorphin (2) and corticotropin-releasing factor (3)-have been found to play a role in the regulation of neurohypophysial hormone secretion, we investigated the effects of CCK on the release of OT and vasopressin (VP) from isolated rat NLs.
MATERIALS AND METHODS
Pituitaries were removed from male Sprague-Dawley rats (200-250 g) and NLs were freed from intermediate lobe tissue under a dissecting microscope. NLs were singly impaled on stimulating electrodes immersed in oxygenated physiologic saline [140 mM NaCl/4.5 mM KCl/1.5 mM MgCl2/2.0 mM CaCl2/10 mM Hepes, pH 7.3/10 mM dextrose/bovine serum albumin (1.5 mg/ml)] maintained at 370C and equilibrated with frequent washes for 90 min prior to starting the experiment. The incubation and stimulus assembly have been described in detail elsewhere (4) . The stream of 02 suffusing the medium was turned off during periods of peptide addition (and for the same period in control preparations) to avoid oxidation of CCK and related peptides, which can destroy their activity. Medium was collected at 5-or 10-min intervals for determination of OT and VP content by specific radioimmunoassay as described (4) . Peptides werf obtained from Peninsula Laboratories, the CCK antagonist L-364,718 was from Merck Sharp & Dohme, and staurosporine was from Kyowa Medex (Tokyo).
For CCK receptor studies, pituitaries were dissected from male Sprague-Dawley rats, rinsed in room temperature normal saline, and frozen directly in Lab-Tek O.C.T. compound embedding matrix over dry ice. They were cut into 12-,m-thick sections at -15'C and thaw mounted onto gelatinized slides. After drying, they were preincubated in 50 mM Tris-HCl (pH 7.4) containing 0.5% bovine serum albumin for 20 min at 240C, then incubated in 10 mM Hepes (pH 6.5) containing 0.5% bovine serum albumin, 0.025% bacitracin, leupeptin (4 gg/ml), 130 mM NaCl, 4.5 mM KCI, 5 mM MgCl2, 1 mM EGTA, and 0.125 nM 1251I-labeled CCK-8 (Amersham) for 2 hr at 240C. After the incubation, slides underwent six 15-min washes in 5% bovine serum albumin at 40C and were dried and apposed to LKB Ultrofilm for 12 days.
RESULTS
To test the effect of CCK on electrically evoked secretion from the NL, we used a low-frequency, low-intensity electrical stimulus protocol that elicits relatively low but reliable levels of OT and VP secretion. This protocol was chosen to minimize the release of endogenous copeptides, so as not to obscure their effects when added experimentally (2) . It was found that CCK-8 (0.1 nM) did not affect the electrically evoked release of OT (Fig. 1A) or VP (unpublished data) but instead caused an episode of secretion that proved to be completely independent of electrical stimulation (Fig. 1B) . Furthermore, unlike the immediate response to electrically stimulated secretion, CCK-evoked secretion was delayed, reaching a peak 40-50 min after first exposure to the peptide (Fig. 1) .
No prior episode of electrical stimulation (i.e., S1) was necessary for the action of CCK, as was found in experiments in which electrical stimulation was omitted altogether (unAbbreviations: CCK, cholecystokinin; CCK-8, cholecystokinin sulfated octapeptide; NL, neural lobe; OT, oxytocin; VP, vasopressin; PKC, protein kinase C.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. electrically evoked secretion of OT using a low-frequency double electrical stimulus (ES) protocol. In these experiments, each NL received two identical periods of ES (arrows), consisting of 1000 pulses of 3 V and 0.5 ms at 6 Hz. Controls (o; n = 3) underwent both stimuli in control medium, while experimental animals (o; n = 3) were exposed to CCK during the second stimulus period, as shown by the solid bar along the abscissa. (B) Experiments (n = 6) in which the second ES was omitted and the effect of CCK (0.1 nM) on resting secretion is shown. (C) Experiments (n = 3) in which the double ES paradigm was used, as in A, in which calcium was omitted from the incubation medium after the S1 phase, as shown by the line along the top of the graph. While the S2 electrically evoked release is abolished, the CCK-induced release is not. Each point represents the mean ± SEM OT release per collection period (5 min in A and C, 10 min in B).
published results). The initial S1 was retained in experiments reported in Fig. 2 Fig. 1B . Data are expressed as S2/S1 ratios, which were determined for each individual preparation as follows: hormone released over 30 min following the standard electrical stimulus (subtracting basal release determined in the period immediately preceding the stimulus) = S1; hormone released during the 110 min following exposure to test substances (subtracting basal level of hormone secretion demonstrated in the period prior to exposure) = S2. Each point represents the mean ± SEM of five to seven experiments at each concentration. The zero point represents S2/S1
values for controls (no peptide exposure during the S2 period).
exposure to CCK or related peptides, as explained in the legend to Fig. 2 .
Electrically evoked secretion from the nerve terminals of the NL is dependent on depolarization-induced calcium influx (5) and does not occur when calcium is absent from the external medium, as shown in Fig. 1C , where release to the second period of electrical stimulation, indicated by the arrow, is abolished. CCK-8, however, evoked OT and VP secretion in calcium-free medium, as shown in Fig. 1C and also in Table 1 (in the latter experiments, there was no second electrical stimulation). CCK also produced secretion in me- Fig. 1B , with no second episode of electrical stimulation. In the calcium-free experiments, calcium was omitted from the medium beginning 30 min after S1 and continuing through the entire S2 phase. Staurosporine (10 nM) and L-364,718 (1 ,M) were added to the medium for the 10-min period prior to and then during the period of CCK exposure. Results are expressed as S2/S1 ratios, which are explained in the legend to Fig. 2 . Briefly, hormone released in response to a standard electrical stimulus = S1, and hormone released in response to peptide = S2.
Control preparations with no additions had S2/S1 ratios of 0.048 ± 0.028 (VP) and 0.039 ± 0.026 (OT). Each value represents the mean ± SEM for five to seven individual experiments. Statistical significance was determined by analysis of variance followed by Dunnet's t test for multiple comparisons. *P < 0.001 vs. CCK-8. tp < 0.01 vs. CCK-8. In other systems such as the acinar cells of the pancreas, snail neurons, and frog oocytes, CCK has been shown to act via mobilization of intracellular calcium stores and activation of protein kinase C (PKC) (6) (7) (8) . Therefore, we used staurosporine, a potent inhibitor of PKC (9), to investigate the possible role of this second messenger system in mediation of the effects of CCK on the NL. As shown in Table 1 , staurosporine effectively inhibited the CCK-8-induced secretion of OT and VP. Staurosporine by itself (10 nM) had no effect on resting or electrically evoked (using the same low-frequency double stimulus protocol shown in Fig. lA) secretion from the NL (unpublished results).
CCK-8 demonstrated a broad range of effective concentrations, as shown in Fig. 2 . The EC50 for both OT and VP release was approximately 0.1 nM, and the maximum response was at 1-10 nM, with a decreasing effect at higher concentrations (100 nM), similar to the CCK dose-response profile reported for stimulation of amylase secretion from the pancreas (10) . A number of CCK-related peptides were compared to CCK-8 with respect to potency in stimulating NL secretion. As shown in Table 1 , unsulfated CCK-8 and gastrin, which shares five C-termiinal amino acids with CCK, were comparable in potency to the sulfated octapeptide. The C-terminal tetrapeptide (CCK-4), however, was a poor secretagogue.
Binding studies have shown that CCK receptors of the central nervous system, with the exception of those in the area postrema, do not discriminate between CCK-8, CCK analogues, and gastrin to the degree that CCK receptors of the gut do (11, 12) . Pharmacological antagonists that show high affinity for the pancreatic CCK receptor are much less potent in inhibiting CCK binding in the central nervous system (13) . At present, no pharmacological antagonists selective for the brain CCK receptor are available. The most potent CCK antagonist is L-364,718 [3S(-)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-yl)-1H-indole-2-carboxamide] (13). This agent was able to block the effect of CCK-8 on NL secretion, but only at a concentration 1000-fold greater than the peptide (Table 1 ). An autoradiographic study of CCK-8 binding in the rat pituitary (Fig. 3) shows that there is a high level of specific binding in the NL relative to the adjacent intermediate and anterior lobes. NLs from animals that had been stalk-sectioned for 2 weeks showed a loss of CCK binding (unpublished results), suggesting that these CCK receptors are on the nerve terminals themselves or are dependent upon the presence of the nerve terminals for their expression.
DISCUSSION
These functional studies demonstrate that the CCK receptor subtype mediating the action of CCK in the NL is similar to the predominant species of brain CCK receptor and not to that found in the area postrema, gastrointestinal tract, and anterior pituitary (12, 14, 15) . In the latter tissues, L-364,718 is a very potent antagonist of CCK, and the sulfated form of CCK-8 is the preferred ligand. CCK-8 is the predominant form of CCK found in the rat neurohypophysis (16) , but we have shown that the five C-terminal amino acids of CCK (Table 1) are sufficient to produce a potent secretion of the neurohypophysial hormones OT and VP.
A previous study did not find any effect of CCK on neurohypophysial hormone release in vitro (1) . This might be explained by the fact that this study used an intensive double electrical stimulus paradigm resulting in a massive release of OT and VP during which the effect of exogenous CCK (9) , suggests that the CCK receptors in the NL may be functionally linked to a second messenger system involving PKC, as is the case in other tissues (6) (7) (8) . In these other tissues, CCK causes a large liberation of intracellular calcium stores, and it may be that the release of calcium stored within the nerve terminals, in conjunction with activation of PKC, is sufficient to trigger exocytosis. A precedent for the release of neurotransmitter in the absence of electrical activity at the release site has been shown for cultured neurons injected with inositol trisphosphate (17) . It is also possible that CCK could act to cause a retraction of the glia, or pituicytes, normally surrounding NL nerve terminals. Such an indirect mode of action would be consistent with the relatively long latency period associated with CCK's secretagogue effect.
The results of our studies suggest that when endogenous CCK is co-released with OT as a result of neural discharges, the neuropeptide could act locally to augment the release of the neurohypophysial hormones in the absence of further electrical stimulation. The physiological context for such a mechanism is unclear at present, but it may be clarified when potent pharmacological antagonists of the central CCK receptor become available.
